BioSpace News Archive

ChromaDex and Nestlé Health Science Announce New Niagen ® Commercial Supply Agreement and $5 Million Investment.

Eyam Vaccines and Immunotherapeutics ltd. today announced a partnership with Mitacs to fund Post-Doctoral Fellowships at the University of British Columbia (UBC).

TeraImmune, Inc., a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to commence the Company’s Phase 1/2a clinical trial to evaluate its lead candidate, TI-168, in congenital Hemophilia A (HA) patients with refractory inhibitors.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022.

Adaptive Biotechnologies Corporation announced a partnership with Epic to integrate the clonoSEQ® Assay into Epic’s comprehensive electronic medical record system.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced data demonstrating the potential of the Company’s novel platform to use various base editing strategies to successfully delete multiple cell surface targets from hematopoietic stem cells (HSCs), potentially enabling next-generation transplants for the treatment of acute myeloid leukemia (AML).

Xtant Medical Holdings, Inc. today announced the closing of the second and final tranche of its previously announced private placement with a select group of accredited investors led by Stavros Vizirgianakis.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced positive written feedback from the U.S. Food and Drug Administration (FDA) for its initial End-of-Phase 2 (EoP2) meeting request to discuss Chemistry, Manufacturing, and Controls (CMC) for its AQST-109 epinephrine sublingual film for the treatment of severe allergic reaction including anaphylaxis.

Orexo AB, announces positive results from the first explorative human clinical study for its nasal epinephrine rescue medication for allergic reactions, OX640.

Forge Biologics announced that Chief Medical Officer Maria Escolar, M.D, MS., will present updated clinical data from the RESKUE Phase 1/2 clinical trial for FBX-101—the Company’s novel gene therapy for the treatment of patients with Krabbe disease—during the 29th Congress of the European Society of Gene & Cell Therapy being held October 11-14, 2022, in Edinburgh, Scotland.